Evidence map›Paper›PMID 40300586›Full record

ReviewHormone research in paediatrics2026

Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibitors: A Position Statement from the Clinical Practice Committee of the European Society for Pediatric Endocrinology.

Christa E Flück, Dulanjalee Kariyawasam, Francesco Ceppi, Shlomit Shalitin, Kanetee Busiah

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christa E FlückPediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
Dulanjalee KariyawasamPediatric Endocrinology, Diabetology, Gynaecology Department, Necker - Enfants Malades University Hospital, Paris Cité University, Paris, France.
Francesco CeppiDivision of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Shlomit ShalitinThe Jesse Z. and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Kanetee BusiahPediatric Endocrinology, Diabetology and Obesity Unit, Division of Pediatric, Department Woman-Mother-Child, Lausanne University Hospital. Faculty of Biology and Medicine, University of Lsaunne, Lausanne, Switzerland, kanetee.busiah@chuv.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are new cancer therapies that function either by blocking the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) or by inhibiting cytotoxic T-lymphocyte antigen 4 (CTLA-4). The utilization of ICIs has improved outcomes for advanced, relapsed, or refractory malignancies in adults and children. Concerns have been raised due to immune-related adverse events (irAEs). The most frequently observed endocrine irAEs in children and adolescents include adrenal insufficiency, diabetes, thyroid dysfunction, and hypophysitis. The Clinical Practice Committee of the European Society for Pediatric Endocrinology (ESPE) aims to highlight the current knowledge and gaps on ICI irAE on the endocrine system in children and adolescents.

Indexed as

Adrenal InsufficiencyDiabetes MellitusEndocrine System DiseasesHypophysitisImmune Checkpoint InhibitorsNeoplasmsAdolescentChildHumansImmune Checkpoint InhibitorsDiabetesHypophysitisImmune checkpoint inhibitorsPrimary arenal insuficiencyThyroiditis

Identifiers

PMID40300586
PMCPMC12176352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.